Novel HER2-Targeted therapy combined with gold nanoparticles

Tetsushi Kubota, Shinji Kuroda, Toshiaki Morihiro, Hiroshi Tazawa, Shunsuke Kagawa, Toshiyoshi Fujiwara

Research output: Contribution to journalReview article

Abstract

Trastuzumab (Tmab) is a humanized monoclonal antibody that binds to the human epidermal growth factor receptor 2 (HER2). It is clinically used for HER2-positive breast and gastric cancers; however, the use of Tmab is restricted to tumors expressing high levels of HER2 (accounting for only 20% of tumors), and Tmab cannot be used for tumors resistant to Tmab. Although novel HER2-Targeted agents have been developed to treat Tmab-resistant tumors, none of these have shown clinical efficacy in gastric cancer patients. Recent developments in nanotechnology have had a significant impact on the field of medicine. Gold nanoparticles (AuNPs), which show characteristics such as in vivo stability and ease of surface functionali- zation, have been developed as therapeutic and contrast agents for medical applications. Previous studies show that AuNPs exert cytotoxic effects through autophagy and apoptosis; therefore, AuNPs in combination with tumor-Targeting antibodies are attractive therapeutic agents. In this study, we developed HER2-Targeted AuNPs (Tmab-AuNPs) and showed that they had a potent antitumor effect on Tmab-resistant cell lines. In addition, Tmab-AuNPs were effective against HER2-negative gastric cancer cell lines when HER2 was artificially overexpressed. Thus, our results indicate that Tmab-AuNPs may overcome the shortcomings of Tmab-based therapy.

Original languageEnglish
Pages (from-to)1237-1239
Number of pages3
JournalJapanese Journal of Cancer and Chemotherapy
Volume43
Issue number10
Publication statusPublished - Oct 1 2016

Fingerprint

Gold
Nanoparticles
Stomach Neoplasms
Therapeutics
Neoplasms
human ERBB2 protein
Trastuzumab
Neoplasm Antibodies
Antibodies, Monoclonal, Humanized
Cell Line
Nanotechnology
Autophagy
Contrast Media
Medicine
Apoptosis
Breast Neoplasms

Keywords

  • Drug resistance
  • Gold nanopartide
  • Trastuzumab

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Cite this

Novel HER2-Targeted therapy combined with gold nanoparticles. / Kubota, Tetsushi; Kuroda, Shinji; Morihiro, Toshiaki; Tazawa, Hiroshi; Kagawa, Shunsuke; Fujiwara, Toshiyoshi.

In: Japanese Journal of Cancer and Chemotherapy, Vol. 43, No. 10, 01.10.2016, p. 1237-1239.

Research output: Contribution to journalReview article

@article{568fb415410746d7bf003236e61554a9,
title = "Novel HER2-Targeted therapy combined with gold nanoparticles",
abstract = "Trastuzumab (Tmab) is a humanized monoclonal antibody that binds to the human epidermal growth factor receptor 2 (HER2). It is clinically used for HER2-positive breast and gastric cancers; however, the use of Tmab is restricted to tumors expressing high levels of HER2 (accounting for only 20{\%} of tumors), and Tmab cannot be used for tumors resistant to Tmab. Although novel HER2-Targeted agents have been developed to treat Tmab-resistant tumors, none of these have shown clinical efficacy in gastric cancer patients. Recent developments in nanotechnology have had a significant impact on the field of medicine. Gold nanoparticles (AuNPs), which show characteristics such as in vivo stability and ease of surface functionali- zation, have been developed as therapeutic and contrast agents for medical applications. Previous studies show that AuNPs exert cytotoxic effects through autophagy and apoptosis; therefore, AuNPs in combination with tumor-Targeting antibodies are attractive therapeutic agents. In this study, we developed HER2-Targeted AuNPs (Tmab-AuNPs) and showed that they had a potent antitumor effect on Tmab-resistant cell lines. In addition, Tmab-AuNPs were effective against HER2-negative gastric cancer cell lines when HER2 was artificially overexpressed. Thus, our results indicate that Tmab-AuNPs may overcome the shortcomings of Tmab-based therapy.",
keywords = "Drug resistance, Gold nanopartide, Trastuzumab",
author = "Tetsushi Kubota and Shinji Kuroda and Toshiaki Morihiro and Hiroshi Tazawa and Shunsuke Kagawa and Toshiyoshi Fujiwara",
year = "2016",
month = "10",
day = "1",
language = "English",
volume = "43",
pages = "1237--1239",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "10",

}

TY - JOUR

T1 - Novel HER2-Targeted therapy combined with gold nanoparticles

AU - Kubota, Tetsushi

AU - Kuroda, Shinji

AU - Morihiro, Toshiaki

AU - Tazawa, Hiroshi

AU - Kagawa, Shunsuke

AU - Fujiwara, Toshiyoshi

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Trastuzumab (Tmab) is a humanized monoclonal antibody that binds to the human epidermal growth factor receptor 2 (HER2). It is clinically used for HER2-positive breast and gastric cancers; however, the use of Tmab is restricted to tumors expressing high levels of HER2 (accounting for only 20% of tumors), and Tmab cannot be used for tumors resistant to Tmab. Although novel HER2-Targeted agents have been developed to treat Tmab-resistant tumors, none of these have shown clinical efficacy in gastric cancer patients. Recent developments in nanotechnology have had a significant impact on the field of medicine. Gold nanoparticles (AuNPs), which show characteristics such as in vivo stability and ease of surface functionali- zation, have been developed as therapeutic and contrast agents for medical applications. Previous studies show that AuNPs exert cytotoxic effects through autophagy and apoptosis; therefore, AuNPs in combination with tumor-Targeting antibodies are attractive therapeutic agents. In this study, we developed HER2-Targeted AuNPs (Tmab-AuNPs) and showed that they had a potent antitumor effect on Tmab-resistant cell lines. In addition, Tmab-AuNPs were effective against HER2-negative gastric cancer cell lines when HER2 was artificially overexpressed. Thus, our results indicate that Tmab-AuNPs may overcome the shortcomings of Tmab-based therapy.

AB - Trastuzumab (Tmab) is a humanized monoclonal antibody that binds to the human epidermal growth factor receptor 2 (HER2). It is clinically used for HER2-positive breast and gastric cancers; however, the use of Tmab is restricted to tumors expressing high levels of HER2 (accounting for only 20% of tumors), and Tmab cannot be used for tumors resistant to Tmab. Although novel HER2-Targeted agents have been developed to treat Tmab-resistant tumors, none of these have shown clinical efficacy in gastric cancer patients. Recent developments in nanotechnology have had a significant impact on the field of medicine. Gold nanoparticles (AuNPs), which show characteristics such as in vivo stability and ease of surface functionali- zation, have been developed as therapeutic and contrast agents for medical applications. Previous studies show that AuNPs exert cytotoxic effects through autophagy and apoptosis; therefore, AuNPs in combination with tumor-Targeting antibodies are attractive therapeutic agents. In this study, we developed HER2-Targeted AuNPs (Tmab-AuNPs) and showed that they had a potent antitumor effect on Tmab-resistant cell lines. In addition, Tmab-AuNPs were effective against HER2-negative gastric cancer cell lines when HER2 was artificially overexpressed. Thus, our results indicate that Tmab-AuNPs may overcome the shortcomings of Tmab-based therapy.

KW - Drug resistance

KW - Gold nanopartide

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=85011101365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011101365&partnerID=8YFLogxK

M3 - Review article

VL - 43

SP - 1237

EP - 1239

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 10

ER -